Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | STAT6 | P42226 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2277283 | 1.00 | FFAR3 (0.39) | FFAR3CYP1A2F10PTPN1MMP2 | |
| SCHEMBL2277287 | 1.00 | FFAR3 (0.39) | FFAR3CYP1A2F10PTPN1MMP2 | |
| SCHEMBL2015443 | 0.93 | FFAR3 (0.37) | FFAR3F10PTPN1MMP2PTPN2 | |
| SCHEMBL17191519 | 0.93 | FFAR3 (0.37) | FFAR3F10PTPN1MMP2PTPN2 | |
| SCHEMBL3384400 | 0.93 | FFAR3 (0.37) | FFAR3F10PTPN1MMP2PTPN2 | |
| SCHEMBL5540894 | 0.91 | LMNA (0.37) | FFAR3F10PTPN1MMP2PTPN2 | |
| SCHEMBL3152534 | 0.86 | — | — | |
| SCHEMBL7374383 | 0.80 | PDK1 (0.35) | CYP1A2LMNA | |
| SCHEMBL21515732 | 0.79 | DPP4 (0.34) | LMNA | |
| Hydrochloric Acid SCHEMBL7367915 | 0.78 | PDK1 (0.34) | CYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4550995-A2 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Universal Display Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-3492528-B1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORP (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20240188434-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-06-06 | — | — | US | disclosed |
| CN-117776829-A | Method for continuously preparing amine compound | 上海巽田科技股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11937503-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| EP-3492528-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Universal Display Corporation (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20190165283-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2019-05-30 | — | — | US | disclosed |
| CN-101952295-B | Pyrrolopyrazine kinase inhibitors | HOFFMANN LA ROCHE | 2013-11-20 | — | — | CN | disclosed |
| EP-2245033-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| WO-2011053948-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-05-05 | — | — | WO | disclosed |
| CN-101952295-A | Pyrrolopyrazine kinase inhibitors | HOFFMANN LA ROCHE | 2011-01-19 | — | — | CN | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | FFAR3 2919/4885CYP1A2 1968/4885F10 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.